Sino Biopharmaceutical Limited (HKG: 1177)

Sino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	8,549	9,452	12,066	10,569	11,259	11,911
Short-Term Investments	-	1,553	-	569.5	956.01	5,618
Trading Asset Securities	4,630	3,113	4,855	4,656	4,217	1,576
Cash & Short-Term Investments	13,179	14,118	16,922	15,794	16,432	19,106
Cash Growth	-15.93%	-16.57%	7.14%	-3.88%	-13.99%	46.71%
Accounts Receivable	7,300	4,596	4,643	4,285	2,914	2,712
Other Receivables	60.97	1,602	1,575	1,164	1,162	630.76
Receivables	7,361	6,199	6,219	5,537	4,076	3,343
Inventory	1,837	1,993	2,329	1,938	1,880	1,659
Prepaid Expenses	2,845	582.57	465.69	234.13	406.58	805.97
Other Current Assets	-	912.71	-	-	-	-
Total Current Assets	25,222	23,806	25,935	23,503	22,794	24,913
Property, Plant & Equipment	9,678	9,912	9,251	8,516	8,392	7,633
Long-Term Investments	27,410	25,181	25,230	25,169	13,857	2,020
Goodwill	700.96	680.45	662.61	647.93	88.93	88.93
Other Intangible Assets	2,422	248.49	278.35	291.56	225.35	821.06
Long-Term Deferred Tax Assets	532.78	567.01	505.15	334.87	463.37	557.35
Long-Term Deferred Charges	-	1,980	973.49	772.46	699.36	503.15
Other Long-Term Assets	738.11	1,230	1,229	1,308	690.21	977.86
Total Assets	66,704	63,605	64,064	60,543	47,210	37,514
Accounts Payable	2,191	1,335	1,884	1,795	1,948	1,809
Accrued Expenses	-	6,716	6,299	5,146	4,190	3,561
Short-Term Debt	-	136.13	136.13	136.13	-	644.62
Current Portion of Long-Term Debt	8,501	11,136	9,663	6,521	1,553	22.13
Current Portion of Leases	10.79	71.49	60.43	64.47	28.7	23.08
Current Income Taxes Payable	406.89	271.87	107.46	101.17	60.7	189.87
Current Unearned Revenue	-	282.6	310.79	238.2	202.22	214.63
Other Current Liabilities	10,839	2,658	1,690	1,344	2,961	1,659
Total Current Liabilities	21,949	22,607	20,151	15,345	10,944	8,123
Long-Term Debt	1,010	1,074	3,934	5,213	12,363	7,885
Long-Term Leases	154.65	298.39	324.26	319.95	264.86	41.27
Long-Term Unearned Revenue	538.91	548.27	749.07	674.45	608.2	480.65
Long-Term Deferred Tax Liabilities	797.21	781.54	831.79	881.59	171.65	423.26
Other Long-Term Liabilities	132.06	125.46	131.08	380.78	439.19	-
Total Liabilities	24,582	25,435	26,121	22,814	24,791	16,953
Common Stock	414.38	414.62	414.9	415.44	415.9	278.45
Additional Paid-In Capital	12,421	12,443	12,484	12,578	12,691	12,967
Retained Earnings	31,847	29,335	28,358	27,215	13,603	11,950
Treasury Stock	-2,109	-1,770	-1,432	-689.35	-469.94	-412.84
Comprensive Income & Other	-9,728	-9,949	-10,078	-9,228	-9,493	-9,834
Total Common Equity	32,845	30,474	29,747	30,291	16,747	14,949
Minority Interest	9,277	7,695	8,197	7,438	5,672	5,612
Shareholders' Equity	42,122	38,170	37,944	37,729	22,420	20,561
Total Liabilities & Equity	66,704	63,605	64,064	60,543	47,210	37,514
Total Debt	9,677	12,716	14,118	12,254	14,210	8,616
Net Cash (Debt)	3,503	1,402	2,804	3,540	2,222	10,490
Net Cash Growth	-15.03%	-50.00%	-20.81%	59.33%	-78.82%	9.15%
Net Cash Per Share	0.19	0.08	0.15	0.18	0.12	0.56
Filing Date Shares Outstanding	18,205	18,347	18,468	18,699	18,781	18,811
Total Common Shares Outstanding	18,205	18,347	18,468	18,699	18,781	18,811
Working Capital	3,273	1,199	5,784	8,158	11,851	16,790
Book Value Per Share	1.80	1.66	1.61	1.62	0.89	0.79
Tangible Book Value	29,722	29,546	28,806	29,352	16,433	14,039
Tangible Book Value Per Share	1.63	1.61	1.56	1.57	0.87	0.75
Buildings	-	4,248	3,871	3,571	3,656	2,854
Machinery	-	7,628	6,692	6,132	5,546	4,541
Construction In Progress	-	1,686	1,804	1,426	987.83	1,365
Leasehold Improvements	-	-	-	-	0.13	0.34

Source: S&P Capital IQ. Standard template. Financial Sources.